{
    "medicine_id": "7e74dae6732c5b84d6ee61d71ca2c826dfdefdf2",
    "platform_id": "DB09120",
    "metadata": {
        "name": "Zuacta Cream",
        "composition": "Zucapsaicin",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated to be used in conjunction with oral COX 2 inhibitors or NSAIDs for the relief of severe pain in adult patients with osteoarthritis of the knee not controlled with oral COX 2 inhibitors or NSAIDs alone for a duration of no more than three months",
            "contraindications": {
                "disease": "Most common adverse effects involved application site reactions such as transient burning and warm sensation Other adverse effects observed in clinical trials are eye irritation arthralgia aggravated osteoarthritis burning sensation headache cough and sneezing Oral LD50 in mouse is 87 5 mg kg in male and 60 mg kg in females Oral LD50 in rats is 90 mg kg in males and 60 mg kg in females L877",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Zucapsaicin mediates an antinociceptive action via acting as an agonist at TRPV1 TRPV1 play an important physiological role of transducing chemical mechanical and thermal stimuli as well as pain transduction and participate in pain modulation and perception They are mainly distributed in C sensory nerve fibers as well as A\u1e9f fibers to transmit sensory information involving inflammatory and neuropathic pain and activation of these channels releasesomatostatin calcitonin gene related peptide CGRP and other neuropeptides neurokinin A kassinin leading to neurogenic inflammation A19720 Zucapsaicin is also reported to affect the peptidergic afferent neurons via a desensitization mechanism to decrease the levels of dorsal root ganglia and sciatic calcitonin gene related peptide CGRP and substance P SP L877",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}